Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Feb 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a potential way to predict a serious condition called hyperprogression in cancer patients receiving immunotherapy. Hyperprogression is when a patient's cancer grows faster after starting treatment, which can significantly affect their quality of life. Researchers have found that a specific protein marker called SAA1 is often higher in patients who experience hyperprogression. The goal of this trial is to confirm whether measuring SAA1 levels in blood and tissue samples can help identify patients at risk for hyperprogression, allowing for earlier intervention.

To participate in this trial, individuals must be over 18 years old and have a specific type of cancer, such as lung, breast, or colorectal cancer, and need to be treated with immune checkpoint inhibitors. Participants will undergo testing to measure their SAA1 levels and will be monitored throughout the study. It's important to note that not everyone will qualify; for example, those with certain serious health conditions or other cancers may be excluded. Overall, this trial aims to improve the understanding of how to better manage cancer treatment and enhance patient outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Over 18 years of age
• • 2. Voluntarily sign informed consent
• • 3. The pathological diagnosis was nasopharyngeal carcinoma, head and neck tumor, lung cancer, breast cancer, stomach cancer, colorectal cancer, glioma, esophageal cancer, liver cancer, bile duct cancer, cervical cancer, prostate cancer, bladder cancer and other malignant tumors
• • 4. Need to be treated with immune checkpoint inhibitors
• • 5. ECOG PS Score: 0/1.
• Exclusion Criteria:
• • 1. There are contraindications to immunotherapy
• • 2. Combined with other tumors (basal cell or squamous cell skin cancer that has been cured, and cervical cancer in situ removed) External)
• • 3. Patients had any serious coexisting medical conditions that could pose an unacceptable risk or negatively affect trial adherence. For example, unstable heart disease requiring treatment, chronic hepatitis, kidney disease, poor disease status, uncontrolled diabetes (fasting blood glucose \> 1.5 × ULN), and mental illness.
• • 4. At the investigator's discretion, those who was not considered to be suitable for participation in the study.